CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-29 | PAKOLA STEVE Chief Medical Officer | Sale | −19,608 | $11.04 | $216K | 213,009 |
| 2026-05-29 | Bennett Jean Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | Bennett Jean Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | Zachary Jennifer Director | Grant or award | +9,807 | 31,871 | ||
| 2026-05-29 | Zachary Jennifer Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | Glucksmann Alexandra Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | Glucksmann Alexandra Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | Fox Allan M. Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | Fox Allan M. Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | Mills Kenneth T. Director | Grant or award | +9,807 | 495,925 | ||
| 2026-05-29 | Mills Kenneth T. Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | Tasse Daniel Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | Tasse Daniel Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | STUMP DAVID C Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | STUMP DAVID C Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | KARABELAS ARGERIS N Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | KARABELAS ARGERIS N Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-29 | MIGAUSKY GEORGE V Director | Grant or award | +9,807 | 28,861 | ||
| 2026-05-29 | MIGAUSKY GEORGE V Director | Grant or award · Stock Options (Right to Buy) | +46,600 | 46,600 | ||
| 2026-05-11 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 | −15,309 | $11.02 | $169K | 232,617 |
Page 2 of 11 · 216 trades